Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, 68, 394 Chen, 2019, The cancer incidence and mortality among children and adolescents during the period of 2010–2014 in Henan Province, China, Cancer Med, 8, 814, 10.1002/cam4.1952 Hosch, 2001, Minimal residual disease in non-small-cell lung cancer, Semin Surg Oncol, 20, 278, 10.1002/ssu.1045 Lequaglie, 2003, Unsuspected residual disease at the resection margin after surgery for lung cancer: fate of patients after long-term follow-up, Eur J Cardiothorac Surg, 23, 229, 10.1016/S1010-7940(02)00750-9 Gu, 2002, Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and survival, Ann Surg, 235, 133, 10.1097/00000658-200201000-00017 Dai, 2013, Molecular diagnosis and prognostic significance of lymph node micrometastasis in patients with histologically node-negative non-small cell lung cancer, Tumour Biol, 34, 1245, 10.1007/s13277-013-0667-5 Liang, 2013, Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC), Transl Lung Cancer Res, 2, 403 Pisters, 2010, Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest oncology group trial S9900, an intergroup, randomized, phase III trial, J Clin Oncol, 28, 1843, 10.1200/JCO.2009.26.1685 Scagliotti, 2012, Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer, J Clin Oncol, 30, 172, 10.1200/JCO.2010.33.7089 Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non–small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774 Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC, N Engl J Med, 379, 2342, 10.1056/NEJMoa1809697 Paz-Ares, 2018, Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer, N Engl J Med, 379, 2040, 10.1056/NEJMoa1810865 Gandhi, 2018, Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer, N Engl J Med, 378, 2078, 10.1056/NEJMoa1801005 Socinski, 2018, Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC, N Engl J Med, 378, 2288, 10.1056/NEJMoa1716948 Liu, 2016, Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease, Cancer Discov, 6, 1382, 10.1158/2159-8290.CD-16-0577 Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, 26, 677, 10.1146/annurev.immunol.26.021607.090331 Forde, 2018, Neoadjuvant PD-1 blockade in resectable lung cancer, N Engl J Med, 378, 1976, 10.1056/NEJMoa1716078 Lim, 2009, Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials, J Thorac Oncol, 4, 1380, 10.1097/JTO.0b013e3181b9ecca Xu, 2018, A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors, J Clin Oncol, 35, e15125, 10.1200/JCO.2018.36.15_suppl.e15125 Boku, 2019, Ann Oncol, 30, 250, 10.1093/annonc/mdy540 Birim, 2005, Survival after pathological stage IA nonsmall cell lung cancer: tumor size matters, Ann Thorac Surg, 79, 1137, 10.1016/j.athoracsur.2004.09.051 Howington, 2013, Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines, Chest, 143, e278S, 10.1378/chest.12-2359 Shapiro, 2014, Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer, Ann Surg, 260, 807, 10.1097/SLA.0000000000000966 Pataer, 2012, Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy, J Thorac Oncol, 7, 825, 10.1097/JTO.0b013e318247504a Hellmann, 2014, Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint, Lancet Oncol, 15, e42, 10.1016/S1470-2045(13)70334-6 Tina Cascone, 2019, Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): clinical and correlative results from the NEOSTAR study, J Clin Oncol, 37 Hodi, 2016, Evaluation of immune-related response criteria and RECIST v1. 1 In patients with advanced melanoma treated with pembrolizumab, J Clin Oncol, 34, 1510, 10.1200/JCO.2015.64.0391 Shi, 2014, A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (Pioneer), J Thorac Oncol, 9, 154, 10.1097/JTO.0000000000000033 Berry, 2018, Presence of even a small ground-glass component in lung adenocarcinoma predicts better survival, Clin Lung Cancer, 19, e47, 10.1016/j.cllc.2017.06.020 Kwiatkowski, 2019, Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): interim analysis and biomarker data from a multicenter study (LCMC3), J Clin Oncol, 37 Tang, 2018, PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression, J Clin Invest, 128, 580, 10.1172/JCI96061 Wu, 2018, Stromal PD-L1-positive regulatory T cells and PD-1-positive CD8-positive T cells define the response of different subsets of non-small cell lung cancer to PD-1/PD-L1 blockade immunotherapy, J Thorac Oncol, 13, 521, 10.1016/j.jtho.2017.11.132 Munari, 2018, PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections, J Thorac Oncol, 13, 1113, 10.1016/j.jtho.2018.04.017